Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Nov 27, 2013; 5(11): 635-641
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.635
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.635
Table 1 Patient baseline and demographic characteristics, and treatment response in the present study
Total | PNALT | Abnormal ALT | P value | |
Number of patients | 278 | 100 | 178 | |
Age (yr) | 55.6 ± 11.4 | 56.2 ± 10.9 | 55.3 ± 11.6 | 0.526 |
Gender (male/female) | 136/142 | 31/69 | 105/73 | < 0.0001 |
AST (IU/L) | 56.6 ± 44.7 | 29.8 ± 12.1 | 71.3 ± 49.1 | < 0.0001 |
ALT (IU/L) | 70.5 ± 64.3 | 27.6 ± 7.2 | 94.6 ± 69.4 | < 0.0001 |
γ-GT (IU/L) | 50.7 ± 57.3 | 26.2 ± 22.1 | 64.1 ± 65.7 | < 0.0001 |
WBC (/mm3) | 5190 ± 1500 | 5060 ± 1490 | 5260 ± 1510 | 0.28 |
Hemoglobin (g/dL) | 14.4 ± 7.1 | 13.5 ± 1.2 | 15.0 ± 8.9 | 0.094 |
Platelets (× 104/mm3) | 17.1 ± 5.6 | 17.7 ± 5.9 | 16.8 ± 5.5 | 0.20 |
Previous treatment (-/+) | 211/67 | 75/25 | 136/42 | 0.90 |
IL-28B SNP(Maj/Min) | 189/89 | 70/30 | 119/59 | 0.68 |
VR/Null response | 203/65 | 84/16 | 129/49 | 0.042 |
RVR (+/-) | 32/200 | 12/70 | 20/130 | 0.93 |
EVR (+/-) | 116/118 | 46/36 | 70/82 | 0.18 |
SVR (+/-) | 143/135 | 56/44 | 87/91 | 0.30 |
Table 2 Baseline characteristics of hepatitis C virus-infected patients, according to interleukin 28B single-nucleotide polymorphism rs8099917
IL-28B rs8099917 | PNALT group (n = 100) | Abnormal ALT group (n = 178) | ||||
Major | Minor | P value | Major | Minor | P value | |
Number of patients | 70 | 30 | 119 | 59 | ||
Age (yr) | 57.7 ± 10.8 | 52.6 ± 10.5 | 0.031 | 55.3 ± 11.3 | 55.4 ± 12.3 | 0.95 |
Gender (male/female) | 21/49 | 10/20 | 0.92 | 68/51 | 37/22 | 0.58 |
AST (IU/L) | 29.3 ± 13.1 | 30.9 ± 9.7 | 0.58 | 69.4 ± 51.4 | 75.4 ± 44.1 | 0.47 |
ALT (IU/L) | 26.8 ± 7.2 | 29.5 ± 7.0 | 0.086 | 92.1 ± 70.4 | 99.5 ± 67.8 | 0.5 |
γ-GT (IU/L) | 21.0 ± 11.5 | 38.4 ± 33.8 | 0.00069 | 54.0 ± 41.3 | 85.1 ± 95.7 | 0.0056 |
WBC (/mm3) | 5130 ± 1440 | 4900 ± 1640 | 0.52 | 5280 ± 1,680 | 5230 ± 1070 | 0.84 |
Hemoglobin (g/dL) | 13.3 ± 1.0 | 13.9 ± 1.5 | 0.02 | 15.3 ± 10.8 | 14.4 ± 1.1 | 0.52 |
Platelets (× 104/mm3) | 17.2 ± 5.7 | 18.8 ± 6.3 | 0.21 | 17.0 ± 5.3 | 16.4 ± 5.8 | 0.49 |
Previous treatment (-/+) | 54/16 | 21/9 | 0.61 | 93/26 | 43/16 | 0.55 |
VR/Null response | 63/7 | 21/9 | 0.027 | 98/21 | 31/23 | 0.000059 |
RVR (+/-) | 9/50 | 3/20 | 0.92 | 17/84 | 3/46 | 0.12 |
EVR (+/-) | 38/21 | 8/15 | 0.029 | 59/44 | 11/38 | 0.00011 |
SVR (+/-) | 44/26 | 12/18 | 0.058 | 67/52 | 20/39 | 0.0079 |
Table 3 Hepatitis C virus genotype 1-infected patient with persistent normal alanine aminotransferase and interleukin 28B single-nucleotide polymorphism
IL-28B rs8099917 | Major | Minor | P value | SVR | Non-SVR | P value |
Number of patients | 54 | 18 | 36 | 36 | ||
Age (yr) | 58.4 ± 10.9 | 54.6 ± 11.0 | 0.20 | 56.6 ± 13.4 | 58.4 ± 8.0 | 0.49 |
Gender (male/female) | 17/37 | 7/11 | 0.77 | 14/22 | 10/26 | 0.45 |
AST (IU/L) | 30.3 ± 14.5 | 34.5 ± 10.3 | 0.29 | 13.2 ± 1.1 | 32.0 ± 6.3 | < 0.00010 |
ALT (IU/L) | 27.5 ± 6.7 | 31.7 ± 5.6 | 0.019 | 27.3 ± 7.4 | 29.8 ± 5.7 | 0.11 |
γ-GT (IU/L) | 21.7 ± 11.9 | 47.3 ± 39.3 | 0.00024 | 19.7 ± 10.6 | 39.2 ± 32.7 | 0.0011 |
WBC (/mm3) | 5020 ± 1410 | 4570 ± 1350 | 0.27 | 5000 ± 1350 | 4780 ± 1470 | 0.51 |
Hemoglobin (g/dL) | 13.3 ± 0.9 | 13.7 ± 1.5 | 0.17 | 13.2 ± 1.1 | 13.5 ± 1.1 | 0.25 |
Platelets (× 104/mm3) | 16.6 ± 6.0 | 17.0 ± 5.6 | 0.80 | 17.1 ± 6.0 | 16.2 ± 5.8 | 0.51 |
Previous Treatment (-/+) | 42/12 | 12/6 | 0.52 | 29/7 | 25/11 | 0.41 |
VR/Null response | 46/8 | 9/9 | 0.0064 | 36/0 | 19/17 | < 0.00010 |
RVR (+/-) | 6/38 | 0/16 | 0.28 | 6/27 | 0/27 | 0.057 |
EVR (+/-) | 25/19 | 1/15 | 0.0013 | 23/10 | 3/24 | < 0.00010 |
SVR (+/-) | 34/20 | 2/16 | 0.00040 | |||
IL-28B SNP rs8099917 | ||||||
(Maj/Min) | 34/2 | 20/16 | 0.00040 |
Table 4 Factors associated with sustained virologic response among hepatitis C virus genotype 1-infected patients with persistent normal alanine aminotransferase by multivariate analysis
Factor | Category | Odds ratio | 95%CI | P value |
IL-28B rs8099917 | Major/Minor | 7.11 | 1.305-38.799 | 0.023 |
EVR | (+/-) | 13.28 | 3.242-54.399 | 0.0003 |
-
Citation: Miyamura T, Kanda T, Nakamura M, Jiang X, Wu S, Nakamoto S, Mikami S, Takada N, Imazeki F, Yokosuka O.
IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J Hepatol 2013; 5(11): 635-641 - URL: https://www.wjgnet.com/1948-5182/full/v5/i11/635.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i11.635